Cannabis Clubs: Germany Introduces Strict Regulations 26 Apr 2024, 8:30 am

The German government is introducing a new law that aims to clamp down on the commercialization of cannabis associations, known locally as “cannabis clubs.” These changes follow recent reforms that were intended to relax regulations on the use and cultivation of cannabis by private associations.

The Cannabis Act (CanG), introduced last month, allows the creation of associations that can supply their members with up to 50 grams of cannabis per month. These changes have been met with mixed reactions, highlighting the difficulty of bringing local laws into line with international standards that still classify cannabis as a controlled substance.

New regulations and their goals

According to a leaked draft law published by Augsburger Allgemeine, the German government is seeking to tighten the regulations on these associations even further. The goal is to prevent any commercial activity that could result from the distribution of cannabis to club members.

The new regulations prohibit cannabis clubs from operating large crops on shared land, which is intended to make it easier for authorities to monitor activities and prevent these initiatives from turning into commercial ventures.

The government plans to tighten the regulations regarding the cannabis consumption law to respond to the concerns of individual states. The aim is primarily to avoid conflicts with European law by preventing the creation of large, commercial plantations that are more difficult to control.

” The competent authority may refuse a permit if the growing areas or greenhouses of a breeders’ association are structurally linked to the growing areas or greenhouses of another breeders’ association or are in their immediate vicinity, ” the draft reads.

Cannabis clubs in Germany will have to limit their activities to small, non-commercial cultivation. Moreover, association members will have to actively participate in the cultivation, not just buy hemp.

Impact on Cannabis Clubs in Germany

The new restrictions could significantly impact the way cannabis associations conduct their business. For example, the inability to employ permanent employees or use the services of external companies will significantly hamper the development and daily functioning of these organizations.

Associations that hoped to benefit from the economic benefits of collective cultivation will have to rethink their operating models and look for alternative methods of operating within the law.

Reactions and consequences for local authorities

Local authorities have been given more powers to oversee cannabis associations, including the possibility of more frequent inspections and greater sanctions for violations.

Bavaria, which opposed the Cannabis Act from the beginning, has already introduced a catalog of penalties for offenses related to CanG, including fines for people possessing more than the permitted amount of cannabis.

This includes a fine of between €500 and €1,000 for anyone caught possessing more than the permitted amount of cannabis, and €1,000 for anyone caught consuming cannabis in the presence of children.

Summary and future

The new regulations in Germany are an important step in the pursuit of a sustainable cannabis policy that simultaneously tries to prevent commercialization and respect international agreements.

The future of cannabis clubs in Germany will depend on how effectively they are able to adapt to the new legal landscape and how local authorities apply the new regulations.

The restrictions introduced by the German government are an attempt to strike a balance between liberalization and control, which is a challenge for all parties involved. As it turns out, the road to legalizing hemp in Germany is full of compromises and unexpected turns, reflecting the global debate about this controversial plant.

__

(Featured image by Pavel Danilyuk via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FaktyKonopne. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Merck Invests Over 300 Million Euros in a New Research Center in Germany 26 Apr 2024, 7:30 am

Merck continues to invest in biotechnology. The pharmaceutical multinational has announced that it will allocate more than 300 million euros to the launch of a new research center in Germany. Specifically , the complex will be located at the group’s headquarters in Darmstadt.

The project is part of an investment program being developed by the German city, for which Merck has contributed around 1.5 billion euros until 2025. The new building will open its doors in 2027 and will employ 550 workers .

With the new investment, Merck will provide solutions in the production of antibodies , mRNA applications and products for biotechnology production, among other research. “With this investment, we are enabling scientific progress for the benefit of millions of patients and customers around the world,” said Belén Garijo, CEO of Merck, in a statement.

Merck to focus on antibody production, mRNA applications and biotech products

The Advanced Research Center of the pharmaceutical group brings together key research for the development of new medicines. The company is also engaged in research into cell culture media and pharmaceutical formulation and purification aids, as well as digital reference materials.

In recent years, Merck has made several investments on a global scale. Last March the group announced that it would disburse another 300 million euros, but for a plant in South Korea specialized in the production of bioprocessing. All in all, Merck has been announcing investments of more than €2 billion since 2020 with the aim of expanding the capabilities and possibilities of biological sciences to meet the growing demand for medicines worldwide.

The Merck group accumulated net sales of 20.99 billion euros in 2023, 1.6% less than in the previous fiscal year, while its gross operating result (ebitda) fell 14.2%, to 5.9 millions of euros. By 2024, the pharmaceutical company plans to return to the path of growth through sales in its Life Science division and the recovery of the semiconductor materials market.

__

(Featured image by RephiLe water via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

E-commerce: Sustainability Becomes a Key Purchasing Criterion in Large Emerging Countries 25 Apr 2024, 12:30 pm

One of the surprising trends revealed by ESW’s Global Voices survey, which surveyed consumers around the world to measure the importance they place on the “sustainability” criteria of the products they buy on E-commerce sites: in India or China, these criteria are more important than in France or the United States. Review of details.

We knew that the inflationary surge of the last two years had reduced the attractiveness of environmentally friendly products and a “sustainable” supply chain in France in favor of purchasing power concerns. This is confirmed in the latest Global Voices report from ESW , the world leader in direct-to-consumer (DTC) e-commerce.

Thus, French consumers are less concerned about “sustainability” in their purchases than they were a year ago with a score of 53 points this year, compared to 59 in 2023, falling below the world average of 55 points*.

But one of the most surprising developments in this report is that consumers in some emerging countries are now significantly more concerned about sustainability than their counterparts in advanced countries. This is the case in India (75 points), the United Arab Emirates (74 points), China (70 points) and Mexico (67 points), which top the list, far ahead of the three countries already mentioned but also Japan (32 points), Germany ( 46 points), the United Kingdom (46 points), Switzerland ( 48 points), Canada (48 points), and the United States (49 points).

“We are surprised to discover that the level of concern consumers have about environmental impact, and what they value most from the brands they use, depends largely on where they live ” comments Martim Avillez Oliveira, Chief Revenue Office of ESW, quoted by this company’s press release. “The data suggests that although French consumers have been encouraged to make environmentally friendly choices for years, the intensity and redundancy of these messages, as well as the increasing pressure that inflation places on households, could drive consumers at a tipping point.”

Sustainability: Young people and more motivated luxury buyers

Among the other trends revealed by this study, the greatest motivation of young people is found almost everywhere in the world. Thus, generation Z has a global average score of 61, generation Y (millennials) 60, generation X 53, and baby boomers barely 49. A trend that we find in France, where, however, the score of Millennials is decreasing (57 against 63 last year).

Additionally, a third of all respondents globally are environmentally conscious shoppers. The survey classifies buyers who scored 80 or higher on the sustainability scale as eco-friendly buyers. Globally, more than half of consumers surveyed (55%) said they were more aware of greenwashing than a year ago, and 27% said they considered environmental transparency. a brand when they made a purchase.

Also note that, according to this study, buyers of luxury products are 1.5 times more likely to be attentive to sustainability issues than others. Likewise, shoppers who value authentic brands are 50% more likely to be eco-friendly shoppers. Overall, 63% of consumers said they value authentic brands and expect “ honesty and transparency about their environmental credentials ” from them.

Finally, consumers who appreciate big brands are also more concerned about the environment with a sustainability score of 62 compared to 47 for others. 32% of brand buyers are likely to be environmentally conscious consumers. Additionally, brand buyers believe that a brand name signifies higher quality and better value. These buyers have high expectations not only for products and services, but also for environmental impact.

The report found that 31% of consumers evaluate sustainable packaging options when shopping online, while 30% consider sustainable shipping options and 29% value reduced packaging overall.

__

(Featured image by Preis_king via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in LE MOCI. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Agadir Signs a Partnership to Boost the Horticultural Sector 25 Apr 2024, 11:30 am

In the wake of the activation process of the Regional Development Company (SDR) Agricultural Innovation, after its validation at the end of the extraordinary session of November 2023 of the Souss-Massa Regional Council, a new stone was brought to the building of this structure. As a reminder, this was created jointly by the Agadir Horticultural Complex (CHA), under the Hassan II Agronomic and Veterinary Institute (IAV) and the Souss-Massa Regional Council.

During a ceremony, held at the end of the week, in Aït Melloul, Agadir, the vision of the SDR and the CHA by 2035 was presented, in particular the strategic partnerships. This vision includes projects falling within the prerogatives of the State, the attributions of the SDR and cooperation projects with the private sector. On this last point, a tripartite memorandum of understanding was sealed between Karim Achengli, president of the Souss-Massa Regional Council, Farid Lekjâa, director of the CHA and Hassan Al Jaber, boss of the Qatari group NAAAS Holding.

This partnership concerns the component of the Agadir International Horticultural Hub, notably the experimental farm covering 23 hectares in the form of production glass greenhouses. This project is part of the Agricultural Innovation action plan which also includes the analysis laboratory, research and development with the center of excellence based on a consortium for research, development and innovation (RDI) in the agricultural field with agricultural professionals. Also worth mentioning is the incubator for agribusiness leaders and an eco-museum which will be built over an area of ​​20 ha in the argan tree biological reserve.

Horticultural sector in Agadir: Two production units for tomatoes and red fruits

Cooperation with the Qatari holding company will concern the aspect linked to agricultural production, in addition to the role assigned to the SDR, in this case the launch of the tomato production unit on 10 ha and another blueberry production unit on 8 ha. In addition to the production players (Agricultural Innovation and NAAAS Holding), the marketing players, recommended as part of this project, are the Dutch Harvset House for tomatoes and the American Driscoll’s for red fruits. Preliminary studies for this project, which will be led by Agricultural Innovation, have already been carried out.

As for the second component of the International Horticultural Hub, it is provided by the training center on two hectares, in the form of a glass greenhouse, which will provide academic training through work-study and certification with the strengthening of the capacities of the SDR. Agricultural Innovation, also involved in the research and development aspect, also has a center of excellence.

This concerns agro-development projects, in particular the development of varieties resistant to viruses and climate variations in addition to the zero residue project and water engineering, with the École normale supérieure de Lyon.

Note that USAID is one of the recommended partners for the development of this R&D component and the center of excellence.

20 startups incubated each year in Agadir

This R&D component is closely linked to another component of this project, in this case the incubator which aims to support 100 startups by 2029. In detail, this structure will aim for 20 startups each year in order to better support project leaders over a period of five years.

The first group of startups will be welcomed in September 2024 with a first startup specializing in the production of virus-resistant seeds and varieties, notably Tobrev, and capable of resisting the cold while adapting to climate change. The aim is to reduce dependence on seeds by capturing 20% ​​of imports which amount to around 76 million euros, mainly tomatoes.

This project will also be carried out with a Spanish partner. Furthermore, with a capacity of 500 beds, the CHA, which already accommodates 476 students, is in the process of increasing its reception capacity. The goal is to increase capacity to 1,200 beds in order to train 1,000 agricultural executives by the year 2034, through the school of engineers and technicians. New specialties will also be introduced (water engineering, horticulture and landscaping, in particular).

In this sense, three schools will be created in Agadir. These are the institutes of horticulture and water engineering as well as the landscape school. On this last point, a master’s degree is in the process of being accredited next September. It should be noted that the SDR Agricultural Innovation has capital of around 5 MDH. It was created by five shareholders including the Souss-Massa Regional Council which will hold the lion’s share of its round, i.e. 49,992 shares out of 50,000. The rest of the actions are shared with the Hassan II Agronomic and Veterinary Institute.

The Agadir Horticultural Complex (CHA) will have five actions while the other entities in the round table (Ministry of the Interior, Chamber of Commerce, Industry and Services “CCIS-Souss-Massa” and Regional Agricultural Chamber Souss-Massa) hold one symbolic share each.

__

(Featured image by planet_fox via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in LES ECO.ma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

MSD Gets Green Light from the European Commission for Keytruda, the World’s best-Selling Drug 25 Apr 2024, 10:30 am

Merck Sharp&Dohme (MSD) receives a boost from Europe. The American laboratory has announced that the European Commission (EC) has approved the compound pembrolizumab, the base of Keytruda, an oncological drug. This is the company’s star drug, the best-selling in 2023 and whose sales the pharmacy expects to represent 50% of sales in 2028. This approval follows the positive resolution of the Committee for Medicinal Products for Human Use (Chmp) issued in February 2024.

“Despite clinical advances for patients with metastatic lung cancer, this pathology continues to be the main cause of cancer death in Europe, reinforcing the need to treat these patients in the early stages of the disease, where we can obtain greater impact,” said Dr. Solange Peters, director of the department of medical oncology and thoracic diseases at the Vaudois University Hospital Center in Lausanne, Switzerland.

MSD closed 2023 with a turnover of 55.5 billion euros, 1% more than in 2022, when it obtained sales of 54.7 billion euros. The pharmaceutical company closed the fourth quarter with 13.5 billion euros in turnover, exceeding Wall Street expectations by 120 million euros. The difference is due to sales of Keytruda and the papilloma vaccine, Gardasil.

MSD has two drugs in the top 10 best-selling drugs in the world: Keytruda and Gardasil

The results given by MSD for the fourth quarter represent a quarterly net loss, but this is an expected figure after the agreement that the company closed with the Japanese pharmaceutical company Daiichi Sankyo to develop three cancer treatments.

The pharmaceutical division of the German multinational invoiced 12.1 billion euros in the fourth quarter, which is 8% more than in the previous period. Keytruda, whose patent expires in 2028, became the best-selling drug in 2023, and the consulting firm Evaluate Pharma predicts that it will continue to lead the top 10, sharing the ranking with Gardasil, also from MSD, in ninth position .

MSD’s oncology treatment, Keytruda, obtained sales of 6.1 billion euros in 2023, 21% more than in the previous period , already before the boost that is expected to be given by the green light from the EC. The turnover generated by Gardasil sales stood at 1.7 billion euros, 27% more than in the fourth quarter of 2022.

__

(Featured image by Marek Studzinsky via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Konvex Created the First Universal API that Integrates Different ERPs in Latin America 25 Apr 2024, 9:30 am

The fintech company Konvex has a presence in Colombia, Mexico and the United States, and has achieved more than 500,000 transactions in accounting reconciliations in nine integrations that have a global market spectrum.

In the era of business digitalization, the implementation of enterprise resource planning (ERP) systems has emerged as a fundamental pillar for the success and efficiency of organizations. These systems not only consolidate information on a single platform, but also integrate all business operations, providing a complete, real-time view of the company’s situation.

Although there is a wide range of ERP software or accounting systems in the market, each one contributes to the growth of organizations. However, for many companies, including SMEs, which make up 99% of the supply in the country, managing multiple ERP systems has become a complex and expensive challenge.

According to a Gartner study, 41% of SMEs say they would not consider a product that does not integrate with their accounting or ERP software. To avoid this problem, Konvex was born, a Colombian fintech with a presence in Colombia, Mexico and the United States, which created the first application programming interface that integrates more than 10 ERPs into a single API (Universal API) in Latin America, which facilitates that companies can integrate accounting and ERP systems from a single access point.

“At Konvex we want fintech and technology companies to be able to easily integrate their services with different ERP and accounting systems using our Universal API, all acting under the form of white label. This saves them extra costs on complex integrations and saves their clients time having to do a manual synchronization in their ERPs. Furthermore, by offering our solution, companies can increase the value proposition of their current products,” explained Joan Rodríguez, CEO of Konvex.

According to Rodríguez, “when companies acquire a provider, whether it is a payment gateway or treasury management platform, they expect it to have integration with their accounting. “They don’t want to have multiple solutions, but everything in one place and that is the headache we avoid.”

That is why Konvex API integrates different ERPs such as Siigo, Alegra, SAP, Oracle Netsuite, Quickbooks, Microsoft 365 and Shopify, among others, in one place, so that companies and fintechs that use the services become providers of business reconciliation. invoices and digital transactions automatically. Likewise, thanks to the Konvex solution, these accounting and ERP systems, which are the largest in Colombia, will be available from a single platform, without the need for additional integration.

“With some APIs, for example Netsuite, that are so complex due to their wide variety of modules, clients prefer to work with us because we simplify all their needs from one place. What we do is be a provider that has everything companies need and with our solution we have saved 80% of time and costs in integrations for organizations that have trusted us. From the first moment our clients integrate their product with Konvex, they can automatically offer all ERP integrations and accounting systems to their clients,” said Rodríguez.

The Konvex API offers numerous benefits so that companies and startups can take advantage of their time and effort in more strategic and innovative activities for their business. Furthermore, by automating the integration process, you significantly reduce the risk of human error, ensuring greater accuracy in financial operations. It also saves costs by eliminating the need to pay for additional cloud servers, maintain multiple APIs, and study documentation, thus optimizing available resources.

What has been the role of Konvex in Colombia?

Since joining the 500 Startups investment fund in 2023, Konvex has impacted around 50 companies, from startups to some larger ones that have been in the market for more than 30 years. In Colombia, fintech is in collaboration with important companies in the sector such as Finaktiva, Vaas, Milio, Payments Way, among others.

Likewise, Konvex has enabled companies to save 30% on the cost of bank reconciliations and 40% on server and storage costs. Likewise, with its solution more than 500,000 API calls have been made, being a pioneer in the Openfinance industry in Latin America. In October 2023, the company raised more than $700,000 in a pre-seed funding round. With these funds, the startup aims to achieve annual growth of more than $1 million in sales and expand to more than 10 countries around the world thanks to its global integrations.

Konvex’s focus is directly between several of its applications to the financial management software used by SMEs in Latin America and the plan is to be able to integrate the most important ERPs in the world. “Our mission is to provide security and reliability to attract companies and make them count on us as allies.

Although we are in an initial stage of operation, we hope to continue strengthening ourselves to position ourselves in more countries.” So that more companies can know the potential of Konvex, the fintech company offers a free level of 1,500 API Calls per month and also its PRO version that has personalized plans for clients with large volumes of transactions.

__

(Featured image by Firmbee via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in LA NOTA ECONOMICA. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

The French Real Estate Crowdfunding is Going through First Crisis 25 Apr 2024, 8:30 am

Tough times for real estate crowdfunding in France. The rise in rates has caused a collapse in real estate purchases, particularly in new properties (-38.4% in 2023 according to the Federation of Real Estate Developers – FPI). Promoters are seeing their unsold stocks grow.

The construction sites, which can only begin beyond a certain marketing threshold, are at a standstill. Margins are shrinking. The social plans announced by giants like Vinci Immobilier, Nexity and Bouygues Immobilier demonstrate the seriousness of the situation.

At the other end of the chain, these discrepancies have consequences for individuals who have invested in real estate crowdfunding

Usually, the time between subscription and repayment rarely exceeds 18 to 24 months. By the time the project ends and the promoter recovers the proceeds from the sales from the buyers, after the last calls for funds. With the crisis, real estate crowdfunding platforms are facing an unprecedented increase in requests for extension of reimbursements. Without being able to finish their projects on time, funded developers do not have the cash flow necessary to return their funds to investors in a timely manner.

Over the past few months, repayment delays have been piling up. “I am currently participating in around ten projects, and 7 of them are late,” explained Guillaume, a crowdfunding investor for 5 years. For the moment, this represents around 15,000 euros blocked. The problem is found on the 4 platforms on which I have invested. “. If the delay is not synonymous with the failure of a project (and therefore a loss for investors), the default rate could nevertheless explode by 2025.

Real estate crowdfunding is experiencing its first crisis

This phenomenon reminds us that the 8 to 12% potential return displayed by projects is accompanied by substantial risk, particularly during periods of market decline. Until now, with the exception of a few isolated failures, crowdfunding investors had not experienced this risk of recession.

History shows, however, that the real estate market is highly cyclical, experiencing a period of sudden decline approximately every ten years. It should be remembered that real estate crowdfunding arrived in France in 2014 – 2015, at the dawn of a new upward cycle driven by the continued fall in rates. The sector is therefore experiencing its first crisis after a decade of continuous improvement.

For the real estate crowdfunding platforms, the challenge is significant: avoid or limit investor losses, preserve their reputation and find growth drivers to compensate for downward cycles in real estate (some generalists have also particularly accelerated on the financing of SMEs traditional).

“Risk is noted on each page when investing in a project,” underlines Guillaume . What is happening today, I would say that it is part of the life of an investor, we know that there is no return without risk. I remain confident in the long term. But what makes you suspicious is when you don’t get any response from the platform, or when you feel like it’s getting in the way.”

A message that the Wiseed platform understood well. In a “ letter to investors ” sent on April 21, Mathilde Iclanzian, its general director, favors transparency regarding the new context. “There are many of you today who are expressing your concern about this situation. Several questions often arise: what is behind this wave of delays in reimbursements? Should we expect an increase in the number of defects? Unfortunately, the answer is most certainly yes, and 2024 will be a pivotal year .

The long email details the measures taken to preserve the interests of investors. Each extension request is subject to a rigorous examination to assess its validity and the financial health of the company concerned. The platform now does not grant any financing without security via mortgages or security trusts. It also states that it has adjusted its contracts to improve flexibility in the repayment of loans and has doubled its resources to manage payment deferrals.

Still difficult months ahead for the French real estate crowdfunding sector

It will probably take many more months for the entire real estate sector to recover and for crowdfunding to regain momentum. Fortunately, certain signals seem to be going in the right direction: according to the Observatoire Crédit Logement , credit rates have had 3 consecutive months of decline, posting an average of 3.90% in March after a peak at 4.21% at the end. of year. With inflation falling, the European Central Bank could also start cutting rates from June, which would be an important new milestone.

But takeoff will likely remain slow. Especially since in new construction, the end of the Pinel system on December 31 will deprive the projects of a large part of rental investors. According to the FPI, these represented almost half of sales since 2016. In 2023, after a tightening of the system, their share fell to 35%.

__

(Featured image by satheeshsankaran via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in ideal-investisseur.fr. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Cannabis in Canada: Trends, Statistics and Social Impact 25 Apr 2024, 7:30 am

Since Canada legalized cannabis, its consumption, sale and impact on society have attracted attention from both supporters and opponents of the decision. Examining the impact of legalization provides important clues about the future direction of drug policy in the country.

Consumer demographics

The latest data from 2023 shows that cannabis is especially popular among younger Canadians. As many as 38.4% of adults aged 18 to 24 and 34.5% of people aged 25-44 admitted to using it in the last 12 months.

In comparison, only 15.5% of people over the age of 45 have used cannabis or products containing cannabinoids . Moreover, approximately 10% of young adults use cannabis daily or almost daily, indicating the intensity and regularity of consumption in this demographic.

Cannabis sales dynamics

Recreational sales in Canada increased 15.8% to $4.7 billion in fiscal year 2022/2023. A key factor in this growth was the growing popularity of vape pens containing cannabis extracts , which accounted for 25% of total sales and grew by 59%. Dried cannabis, however, remains the market leader, accounting for almost two-thirds (64.9%) of sales. The average Canadian of legal age spends $150 a year on cannabis, with the federal and provincial governments taking in about 40% of that money.

The legalization of cannabis in Canada has had a significant impact on drug-related crime. Overall, cannabis crimes have declined, and most current crimes involve illegal import and export. In 2022, 67% of the 10,824 drug crimes involved illegal smuggling, while only 12% involved possession.

Research and innovation in consumption monitoring

In Canada, innovative methods such as wastewater analysis are being used to monitor cannabis consumption levels. This approach allows for anonymous and almost instantaneous data from entire communities. Wastewater testing helps understand how cannabis consumption has changed over the years and is also used in other studies, such as during the COVID-19 pandemic.

Despite many positives, cannabis legalization also brings challenges. Research shows that almost three-quarters (72.4%) of people who smoke cannabis daily may have trouble controlling their use. Additionally, despite overall market growth, cannabis sales declined 2.9% in 2023, suggesting possible market saturation or changes in consumer preferences.

The legalization of cannabis in Canada has opened up new opportunities for research on its impact on society. Data from a variety of sources, including wastewater, sales market, and crime analysis, demonstrate the complexity of this issue. Analyzing the effects of legalization is crucial to future policy decisions and shaping laws that best meet the needs of Canadian society.

__

(Featured image by Pavel Danilyuk via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FaktyKonopne. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

PharmaMar Increases Profit by 64% in the First Quarter, Up To 2.3 Million 24 Apr 2024, 9:30 am

PharmaMar improves its profits after the collapse of 2023. The Spanish pharmaceutical company registered a net profit of 2.3 million euros in the first quarter of this year, which represents an increase of 64% compared to the profits obtained during the same period of the year. previous year , as reported this Tuesday to the National Securities Market Commission (Cnmv).

PharmaMar closed 2023 with a net profit of 1.14 million euros, which represents a decrease of almost 98% compared to the previous year , when it earned 49.36 million euros. The company recorded total revenues of 158.15 million euros, 19.45% less, due to the impact of the arrival of the generic trabectedin to the European market.

The firm has achieved this benefit as a result of a positive financial result in the amount of 1.5 million euros, compared to losses of 600,000 euros in March 2023, as well as a positive income tax in the amount of 5. 1 million euros, compared to 4.6 million in March 2023 , after the collection of the part of the deductions for investment in Research and Development (R&D) corresponding to the 2022 financial year, which have been monetized.

Likewise, it recorded total revenues of 38 million euros, which represents an increase of 12% compared to the 34 million euros reported in the first quarter of 2023.

PharmaMar invested 27.2 million euros in R&D

Recurring income, which results from net sales plus royalties received from its partners, increased by 15%, to 31.7 million euros , compared to 27.4 million in the same period of the previous year.

Sales of Yondelis in the European market, after the entry of generics, register a total of 5.2 million euros, compared to 8.1 million euros in the first quarter of 2023 .

As of March 31, 2024, royalty income amounted to 12.7 million euros, which represents an increase of 14% compared to the same period of the previous year. These revenues include royalties received from its partner Jazz Pharmaceuticals for sales of lurbinectedin in the United States, which have increased 13% to €11.6 million.

PharmaMar has specified that the royalties corresponding to the first quarter of 2024 are an estimate, given that the information on the sales made by Jazz is not available at the date of publication of its report. If there is any divergence, it will be corrected in the following quarter.

To the royalties received from Jazz Pharmaceuticals, we must add royalties from sales of Yondelis, from its partners in the United States and Japan, amounting to 1.1 million euros in the first quarter of 2024 compared to 0.9 million in euros recorded in the same period of the previous year .

Investment in R&D stands at 27.2 million euros, which represents an increase of 29% compared to the same period of the previous year .

Finally, PharmaMar debt decreased by three million euros to 36.8 million euros , while the cash and equivalents position at the end of the first quarter stood at 164.4 million euros.

__

(Featured image by Jakub Żerdzicki via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Cannabis Reform in Belgium: What Changes Does the Latest Report Propose 24 Apr 2024, 8:30 am

Belgium, like many countries around the world, faces drug policy challenges, particularly in the context of cannabis. Recent Senate reports shed light on the failures of the current system, pointing to the need for reforms and adapting the law to contemporary realities and social challenges.

The origins of Belgian drug policy date back to 1921, when a law was established to regulate and control drug trafficking. For over a hundred years, this law has remained almost unchanged, which today leads to numerous complications and problems, both legal and social.

The Senate report clearly points to the ambiguity of the current regulations, which not only makes their application difficult, but also introduces society into a state of legal uncertainty. This, in turn, undermines citizens’ trust in the justice system. Additionally, the report notes that the increase in THC concentration in cannabis varieties available on the black market is a direct result of the current prohibition.

Statistics and realities of cannabis consumption in Belgium

The report shows that around a quarter of the Belgian population has had experience with cannabis, and 8% of those who consume it show consumption patterns that could be considered problematic. These data highlight the urgent need to rethink existing regulations in the context of public health and social safety.

The political debate on drug policy reform in Belgium is deeply divided. On the one hand, there are reformers such as Julien Uyttendaele, who propose easing regulations and introducing solutions such as cannabis clubs aimed at limiting the black market. On the other hand, conservative voices like MR’s Philippe Dodrimont emphasize the health and social risks associated with legalization.

Reform proposals are hotly debated in Belgian society. Supporters of change argue that the current system not only fails to stop consumption, but contributes to the increase in drug-related crime. Opponents of the change fear that legalization could lead to increased consumption among young people and worsen health problems, but these fears are regularly allayed by studies conducted in countries where cannabis is legal.

Conclusions and recommendations of the report

The report ends with a series of recommendations, including a call for a new, more transparent and fair legal system. It is also recommended that people using cannabis for personal purposes and not disturbing public order have access to free psychological and medical counseling.

The reform of drug policy in Belgium is not only an opportunity to adapt the law to the realities of the 21st century, but also an opportunity to increase public safety and health. The discussion about the future of cannabis in Belgium is far from over, but it is clear that the current system requires significant changes.

__

(Featured image by sergeitokmakov via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FaktyKonopne. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us